Apr. 11, 2019

INVESTORS KEEN TO PUT MONEY INTO AMR SMES - BIOCOM CONFERENCE REPORT

nvestments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life Sciences, two new financing initiatives, which focus on innovations developed by SMEs, were presented to 200+ AMR stakeholders.

Whilst the REPAIR impact fund, launched by Novo Holdings in late February, will provide €135m over the next 3-5 years as convertible loan or royalty-based funding to SME-developed new anti-infective modalities, the UNCTAD (United Nations Conference on Trade and Development) plans to help establishing an unconventional funding vehicle for SMEs in the AMR field in the long-term.

Conference Report here